Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Current Valuation Ratios
| Illumina Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||
| Current share price (P) | $408.14 | |||||||||||||
| No. shares of common stock outstanding | 156,300,000 | |||||||||||||
| Growth rate (g) | 20.99% | |||||||||||||
| Earnings per share (EPS) | $4.20 | |||||||||||||
| Next year expected EPS | $5.08 | |||||||||||||
| Operating profit per share | $3.71 | |||||||||||||
| Sales per share | $20.72 | |||||||||||||
| Book value per share (BVPS) | $30.03 | |||||||||||||
| Valuation Ratios (Price Multiples) | ||||||||||||||
| Price to earnings (P/E) | 97.24 | 110.53 | 29.07 | 18.20 | 43.67 | 53.98 | 21.99 | 24.38 | 20.11 | 21.03 | 18.01 | 37.23 | 33.74 | |
| Price to next year expected earnings | 80.37 | 599.18 | 21.56 | 16.58 | 40.27 | 41.42 | 30.24 | 21.47 | — | 22.74 | 15.31 | 32.84 | 28.75 | |
| Price-earnings-growth (PEG) | 4.63 | — | 0.83 | 1.86 | 5.17 | 1.78 | — | 1.79 | — | — | 1.02 | 2.79 | 1.94 | |
| Price to operating profit (P/OP) | 109.99 | 30.99 | 24.69 | 12.84 | 33.65 | 42.36 | 18.67 | 25.85 | 17.30 | 11.47 | 22.68 | 32.22 | 31.96 | |
| Price to sales (P/S) | 19.70 | 7.64 | 6.38 | 2.66 | 6.42 | 17.09 | 6.47 | 6.94 | 5.65 | 2.61 | 5.66 | 5.60 | 11.11 | |
| Price to book value (P/BV) | 13.59 | — | 25.89 | 6.95 | 3.00 | 41.98 | 8.24 | 8.02 | 6.98 | 1.89 | 2.60 | 4.67 | 7.15 | |
Based on: 10-K (reporting date: 2020-12-31).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
The valuation multiples for the period between 2016 and 2020 exhibit a general trend of stability followed by a significant expansion across all measured metrics in the final year. While ratios remained within relatively consistent ranges from 2016 through 2019, the 2020 fiscal year shows a sharp increase in the premiums paid relative to earnings, operating profit, sales, and book value.
- Earnings and Operating Profit Multiples
- The Price to earnings (P/E) ratio fluctuated between 43.43 and 52.01 from 2016 to 2019, suggesting a consistent market valuation of earnings during this window. This stability was disrupted in 2020, when the P/E ratio spiked to 109.92. A mirroring pattern is observed in the Price to operating profit (P/OP) ratio, which ranged from 40.99 to 53.47 during the first four years before climbing drastically to 124.33 in 2020.
- Revenue Multiples
- The Price to sales (P/S) ratio demonstrated a gradual increase from 10.03 in 2016 to a peak of 12.89 in 2018, followed by a slight contraction to 12.28 in 2019. In 2020, the P/S ratio experienced a substantial surge, reaching 22.26, which represents nearly a twofold increase over the previous year's valuation.
- Asset-based Multiples
- The Price to book value (P/BV) ratio remained elevated throughout the period, generally oscillating between 9.43 and 11.79 from 2016 to 2019. Similar to other metrics, a sharp upward movement occurred in 2020, with the ratio increasing to 15.36.
The synchronized escalation of all valuation ratios in 2020 indicates a significant shift in market sentiment or a substantial divergence between the stock price and the company's underlying financial fundamentals. The disproportionate rise in P/E and P/OP compared to P/S suggests that the increase in valuation was more pronounced relative to profitability than it was relative to top-line revenue.
AI Ask an analyst for more
Price to Earnings (P/E)
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 145,900,000 | 147,000,000 | 147,000,000 | 147,000,000 | 146,300,000 | |
| Selected Financial Data (US$) | ||||||
| Net income attributable to Illumina stockholders (in millions) | 656) | 1,002) | 826) | 726) | 463) | |
| Earnings per share (EPS)2 | 4.50 | 6.82 | 5.62 | 4.94 | 3.16 | |
| Share price1, 3 | 494.24 | 296.00 | 292.20 | 220.44 | 164.46 | |
| Valuation Ratio | ||||||
| P/E ratio4 | 109.92 | 43.43 | 52.00 | 44.63 | 52.01 | |
| Benchmarks | ||||||
| P/E Ratio, Competitors5 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 Data adjusted for splits and stock dividends.
2 2020 Calculation
EPS = Net income attributable to Illumina stockholders ÷ No. shares of common stock outstanding
= 656,000,000 ÷ 145,900,000 = 4.50
3 Closing price as at the filing date of Illumina Inc. Annual Report.
4 2020 Calculation
P/E ratio = Share price ÷ EPS
= 494.24 ÷ 4.50 = 109.92
5 Click competitor name to see calculations.
Between 2016 and 2020, the valuation metrics exhibit a transition from a period of steady growth to a phase of significant valuation expansion. While the equity price maintained a consistent upward trajectory throughout the period, the relationship between price and earnings shifted dramatically in the final year.
- Share Price Dynamics
- A continuous increase in share price is observed, rising from 164.46 US$ in 2016 to 494.24 US$ in 2020. The most pronounced acceleration occurred between 2019 and 2020, during which the price increased by approximately 66.9%.
- Earnings per Share (EPS) Performance
- Earnings displayed a positive growth trend from 2016 through 2019, ascending from 3.16 US$ to a peak of 6.82 US$. However, this trajectory reversed in 2020, with EPS declining to 4.50 US$, representing a notable contraction in profitability compared to the preceding year.
- Price-to-Earnings (P/E) Ratio Analysis
- From 2016 to 2019, the P/E ratio remained relatively stable, fluctuating within a range of 43.43 to 52.01, which suggests a consistent market valuation relative to earnings growth. In 2020, the ratio surged to 109.92. This sharp expansion was driven by the simultaneous occurrence of a record share price and a decline in earnings, indicating a substantial increase in the valuation multiple and a decoupling of the market price from immediate earnings performance.
AI Ask an analyst for more
Price to Operating Profit (P/OP)
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 145,900,000 | 147,000,000 | 147,000,000 | 147,000,000 | 146,300,000 | |
| Selected Financial Data (US$) | ||||||
| Income from operations (in millions) | 580) | 985) | 883) | 606) | 587) | |
| Operating profit per share2 | 3.98 | 6.70 | 6.01 | 4.12 | 4.01 | |
| Share price1, 3 | 494.24 | 296.00 | 292.20 | 220.44 | 164.46 | |
| Valuation Ratio | ||||||
| P/OP ratio4 | 124.33 | 44.17 | 48.64 | 53.47 | 40.99 | |
| Benchmarks | ||||||
| P/OP Ratio, Competitors5 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 Data adjusted for splits and stock dividends.
2 2020 Calculation
Operating profit per share = Income from operations ÷ No. shares of common stock outstanding
= 580,000,000 ÷ 145,900,000 = 3.98
3 Closing price as at the filing date of Illumina Inc. Annual Report.
4 2020 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 494.24 ÷ 3.98 = 124.33
5 Click competitor name to see calculations.
Between 2016 and 2020, a consistent upward trajectory in share price is observed, rising from 164.46 US$ to 494.24 US$. This growth reflects a substantial increase in market valuation over the period, with the most pronounced acceleration occurring between 2019 and 2020.
- Operating Profit Per Share Trends
- Operating profit per share demonstrated a period of steady growth from 2016 through 2019, increasing from 4.01 US$ to a peak of 6.70 US$. However, this trend reversed in 2020, with a decline to 3.98 US$, marking a return to levels nearly identical to those seen at the start of the analyzed period.
- Price to Operating Profit (P/OP) Dynamics
- The P/OP ratio remained within a relatively stable range of 40.99 to 53.47 between 2016 and 2019. In 2020, the ratio experienced a sharp expansion, increasing to 124.33.
- Valuation Divergence
- A significant divergence is noted in 2020, where the combination of a peak share price and a simultaneous contraction in operating profit per share led to a dramatic increase in the P/OP multiple. This indicates that the market valuation became decoupled from current operating profitability, suggesting that the valuation was driven by factors other than immediate operating performance.
AI Ask an analyst for more
Price to Sales (P/S)
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 145,900,000 | 147,000,000 | 147,000,000 | 147,000,000 | 146,300,000 | |
| Selected Financial Data (US$) | ||||||
| Revenue (in millions) | 3,239) | 3,543) | 3,333) | 2,752) | 2,398) | |
| Sales per share2 | 22.20 | 24.10 | 22.67 | 18.72 | 16.39 | |
| Share price1, 3 | 494.24 | 296.00 | 292.20 | 220.44 | 164.46 | |
| Valuation Ratio | ||||||
| P/S ratio4 | 22.26 | 12.28 | 12.89 | 11.77 | 10.03 | |
| Benchmarks | ||||||
| P/S Ratio, Competitors5 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 Data adjusted for splits and stock dividends.
2 2020 Calculation
Sales per share = Revenue ÷ No. shares of common stock outstanding
= 3,239,000,000 ÷ 145,900,000 = 22.20
3 Closing price as at the filing date of Illumina Inc. Annual Report.
4 2020 Calculation
P/S ratio = Share price ÷ Sales per share
= 494.24 ÷ 22.20 = 22.26
5 Click competitor name to see calculations.
The Price-to-Sales (P/S) ratio exhibits a general upward trajectory over the five-year period from 2016 to 2020, indicating a significant expansion in the market valuation of the company relative to its revenue generation.
- Share Price Trends
- A consistent increase in share price is observed, rising from 164.46 US$ in 2016 to 494.24 US$ by 2020. The most substantial growth occurred between 2019 and 2020, where the price increased by approximately 66.6%.
- Sales per Share Performance
- Revenue efficiency, measured as sales per share, grew steadily from 16.39 US$ in 2016 to a peak of 24.10 US$ in 2019. However, a reversal occurred in 2020, with sales per share declining to 22.20 US$.
- P/S Ratio Analysis
- The P/S ratio rose moderately from 10.03 in 2016 to 12.89 in 2018, followed by a slight correction to 12.28 in 2019. A sharp spike is observed in 2020, where the ratio reached 22.26. This dramatic increase was driven by the simultaneous occurrence of a surge in share price and a contraction in sales per share, suggesting that the valuation in 2020 was driven by factors other than immediate revenue growth.
The divergence between revenue performance and market valuation became most pronounced in 2020, resulting in a valuation multiple that is more than double the 2016 baseline.
AI Ask an analyst for more
Price to Book Value (P/BV)
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 145,900,000 | 147,000,000 | 147,000,000 | 147,000,000 | 146,300,000 | |
| Selected Financial Data (US$) | ||||||
| Total Illumina stockholders’ equity (in millions) | 4,694) | 4,613) | 3,758) | 2,749) | 2,197) | |
| Book value per share (BVPS)2 | 32.17 | 31.38 | 25.56 | 18.70 | 15.02 | |
| Share price1, 3 | 494.24 | 296.00 | 292.20 | 220.44 | 164.46 | |
| Valuation Ratio | ||||||
| P/BV ratio4 | 15.36 | 9.43 | 11.43 | 11.79 | 10.95 | |
| Benchmarks | ||||||
| P/BV Ratio, Competitors5 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 Data adjusted for splits and stock dividends.
2 2020 Calculation
BVPS = Total Illumina stockholders’ equity ÷ No. shares of common stock outstanding
= 4,694,000,000 ÷ 145,900,000 = 32.17
3 Closing price as at the filing date of Illumina Inc. Annual Report.
4 2020 Calculation
P/BV ratio = Share price ÷ BVPS
= 494.24 ÷ 32.17 = 15.36
5 Click competitor name to see calculations.
Between December 31, 2016, and December 31, 2020, a consistent upward trajectory in both share price and book value per share is observed, though the growth rates diverged significantly in the final period. While the underlying book value grew steadily, the market valuation expanded more aggressively, leading to a volatile price-to-book value (P/BV) ratio.
- Share Price Performance
- The share price exhibited sustained growth over the five-year period, rising from 164.46 US$ in 2016 to 494.24 US$ by the end of 2020. The most pronounced increase occurred between 2019 and 2020, where the price surged from 296.00 US$ to 494.24 US$, representing a substantial acceleration in market valuation.
- Book Value per Share (BVPS) Growth
- The BVPS demonstrated a steady and linear increase, climbing from 15.02 US$ in 2016 to 32.17 US$ in 2020. This consistent rise indicates a progressive accumulation of net assets relative to the number of shares outstanding, although the growth rate slowed slightly between 2019 and 2020.
- Price to Book Value (P/BV) Interpretation
- The P/BV ratio remained relatively stable between 10.95 and 11.79 from 2016 through 2018. A contraction occurred in 2019, with the ratio dropping to 9.43, suggesting a period where the share price growth lagged behind the growth of the book value. However, 2020 saw a sharp spike to 15.36, the highest ratio in the period analyzed. This indicates that by the end of 2020, the market was pricing the equity at a significant premium over its accounting value, driven primarily by the rapid increase in share price relative to the modest gain in BVPS.
AI Ask an analyst for more